Patents by Inventor Wynn A. Volkert

Wynn A. Volkert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5516940
    Abstract: A compound and method of making a compound for use as a diagnostic or therapeutic pharmaceutical comprises either a phosphorous or germanium core and at least two hydrazine groups forming a ligand for bonding to a metal extending from the phosphorous or germanium core.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: May 14, 1996
    Assignee: Curators of the University of Missouri
    Inventors: Kattesh V. Katti, Wynn A. Volkert, Alan R. Ketring, Prahlad R. Singh
  • Patent number: 5478474
    Abstract: The method of treating liquid waste in a media is accomplished by exposing the media to phosphinimines and sequestering .sup.99 Tc from the media by the phosphinimine (PN) functionalities. The system for treating the liquid waste in the media includes extraction of .sup.99 TcO.sub.4.sup.- from aqueous solutions into organic solvents or mixed organic/polar media, extraction of .sup.99 Tc from solutions on a solid matrix by using a container containing PN functionalities on solid matrices including an inlet and outlet for allowing flow of media through an immobilized phosphinimine ligand system contained within the container. Also, insoluble suspensions of phosphinimine functionalities on solid matrices in liquid solutions or present on supported liquid membranes (SLM) can be used to sequester .sup.99 Tc from those liquids.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: December 26, 1995
    Assignee: Curators of the University of Missouri
    Inventors: Kattesh V. Katti, Wynn A. Volkert, Prahlad Singh, Alan R. Ketring
  • Patent number: 5300279
    Abstract: Particle-emitting radionuclides, e.g. Gd-159, Ho-166, Lu-177 and Yb-175, have been complexed with organic aminoalkylenephosphonic acids. These complexes have been found useful in compositions for the therapeutic treatment of calcific tumors or the relief of bone pain in animals.
    Type: Grant
    Filed: December 19, 1990
    Date of Patent: April 5, 1994
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, Joseph R. Garlich, William F. Goeckeler, Davis A. Wilson, Wynn A. Volkert, David E. Troutner
  • Patent number: 5066478
    Abstract: Particle-emitting radionuclides, e.g. Gd-159, Ho-166, Lu-177 and Yb-175, have been complexed with organic aminoalkylenephosphonic acids wherein the nitrogen and phosphorus are interconnected by an alkylene group or substituted alkylene group. These complexes have been found useful in compositions for the therapeutic treatment of calcific tumors in animals and in relief of bone pain.
    Type: Grant
    Filed: January 30, 1990
    Date of Patent: November 19, 1991
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, David A. Wilson, Wynn A. Volkert, David E. Troutner, William F. Goeckeler
  • Patent number: 4898724
    Abstract: Particle-emitting radionuclides, e.g. Samarium-153, have been complexed with organic aminoalkylenephosphonic acids wherein the nitrogen and phosphorus are interconnected by an alkylene group or substituted alkylene group. These complexes have been found useful in compositions for the therapeutic treatment of calcific tumors in animals.
    Type: Grant
    Filed: May 14, 1987
    Date of Patent: February 6, 1990
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, David A. Wilson, Wynn A. Volkert, David E. Troutner, William F. Goeckeler
  • Patent number: 4897254
    Abstract: Certain particle-emitting radionuclides, e.g. Samarium-153, have been complexed with certain alkylenepolyaminocarboxylic acid chelants. Compositions containing these complexes have been found useful in the treatment of calcific tumors in animals. The stability constant, log K, of the useful complexes is from about 14 to about 17 and the molar ratio of chelant to radionuclide in the compositions is such that the chelant is present in an amount sufficient to inhibit uptake of the radionuclide by soft tissue.
    Type: Grant
    Filed: March 3, 1987
    Date of Patent: January 30, 1990
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, Wynn A. Volkert, David A. Wilson, David E. Troutner, William F. Goeckeler
  • Patent number: 4615876
    Abstract: Stable neutral-lipophilic complexes of technetium-99m (Tc-99m) useful as diagnostic radionuclidic imaging agents are formed by complexing technetium-99m pertechnetate with alkylene amine oximes (viz. propylene amine oxime) in aqueous solutions under reducing conditions. The complexes have a zero charge, contain an O--H--O ring closure bond, and are sufficiently stable for parental administration in imaging by scintillation scanning. Substituents can be attached to the C.sub.2 to C.sub.4 alkylene carbon backbone of the tetradentate amine oxime ligands to structurally modify them and produce a variety of Tc-99m-radiopharmaceuticals with specific body imaging applications.
    Type: Grant
    Filed: April 25, 1983
    Date of Patent: October 7, 1986
    Assignee: Curators of the University of Missouri
    Inventors: David E. Troutner, Wynn A. Volkert
  • Patent number: 4606907
    Abstract: New stable complexing agents for radionuclides which are phosphonate derivatives of certain polyamidoamines have been found which are useful in imaging the skeletal system in animals. Even though the complexing agents have high molecular weights the complexes clear rapidly and very efficiently through the kidneys, with large amounts being taken up in the bone. The ratio of uptake in bone to that in surrounding soft tissue is high even at relatively short times after injection.
    Type: Grant
    Filed: July 2, 1984
    Date of Patent: August 19, 1986
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, Wynn A. Volkert, David A. Wilson
  • Patent number: 4582698
    Abstract: The imaging of cardiac infarcts with complexed radioactive metals is improved by employing as the complexing agent a compound of the formula ##STR1## wherein substituents A, B, X and Y are each independently selected from radicals including hydrogen, hydroxyalkyl (wherein the alkyl group contains 2-6 carbon atoms), methylenephosphonic, methylene-, ethylene-, and propylenesulfonic, carboxylic acid radicals (having 2-4 carbon atoms) and the alkali or alkaline earth metal, ammonia and amine salts thereof and wherein at least one A, B, X and Y is methylenephosphonic acid or a salt thereof. In particular Tc-99m complexes have been found useful for imaging damaged cardiac tissue.
    Type: Grant
    Filed: September 19, 1983
    Date of Patent: April 15, 1986
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, David A. Wilson, Wynn A. Volkert
  • Patent number: 4560548
    Abstract: Radionuclide complexes of phosphonate derivatives of bis(aminoalkyl)piperazine have been found which are useful for imaging and/or treating therapeutically the skeletal system to detect and treat bone tumors. These complexes clear readily through the kidneys and the ratio of uptake in bone to that in surrounding soft tissue is high.
    Type: Grant
    Filed: April 10, 1984
    Date of Patent: December 24, 1985
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, David A. Wilson, Wynn A. Volkert, Druce K. Crump
  • Patent number: 4515767
    Abstract: Complexes of radionuclides with a compound of the formula ##STR1## wherein substituents A, B, X and Y are each independently selected from radicals including hydrogen, hydroxyalkyl (wherein the alkyl group contains 2-6 carbon atoms) phosphonic, sulfonic, methylenephosphonic, methylene-, ethylene- and propylene-sulfonic, carboxylic acid radicals (having 2-4 carbon atoms) and the alkali or alkaline earth metal, ammonia and amine salts, thereof and wherein at least one A, B, X and Y is methylenephosphonic acid or a salt thereof. Tc-99m complexes have been found useful for imaging the skeletal structure of animals.
    Type: Grant
    Filed: June 20, 1983
    Date of Patent: May 7, 1985
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, David A. Wilson, Wynn A. Volkert
  • Patent number: 4508704
    Abstract: New stable complexing agents for Tc-99m which are phosphonate derivatives of bicycloheptane bis(alkylamines) have been found which are useful in imaging the skeletal system in animals. The complexes readily clear through the kidneys with large amounts being taken up in the bone. The ratio of uptake in bone to that in soft tissue is high.
    Type: Grant
    Filed: February 27, 1984
    Date of Patent: April 2, 1985
    Assignee: The Dow Chemical Company
    Inventors: Jaime Simon, David A. Wilson, Wynn A. Volkert